Increasing payer support and reimbursement coverage, enabling broader patient access and long-term market growth Government Initiatives Supporting the Obesity GLP-1 Market As obesity is increasingly recognized as a chronic, high-burden disease, government initiatives are playing a key role in supporting the obesity GLP-1 market
Individual response varies based on genetics, current metabolic state, and adherence to the protocol
Revuforjs approval was supported by data from 104 patients enrolled in the Phase I/II AUGMENT-101 study, in which 21% of treated patients reached complete remission or complete remission with partial hematological recovery
Picture date: Wednesday August 27, 2025
Introduction Obesity is a chronic disease and is considered a global epidemic, with high associations with but not limited to cardiovascular diseases, type 2 diabetes mellitus (T2DM), several malignancies, chronic kidney disease, metabolic dysfunctionassociated steatosis liver disease (MASLD) and mental disorders [1]